Trials / Withdrawn
WithdrawnNCT00175864
Open Label Study (Everyone Who Participates Receives Drug) to Further Determine How Safe and Effective Oral Treatment of Seletracetam is in Patients With Refractory Epilepsy.
Open Label, Multicenter Study of the Safety and Efficacy of Oral Treatment With Immediate Release Seletracetam (Ucb 44212) at Individualized Doses up to a Maximum of 160mg/Day in Refractory Epileptic Patients.
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 16 Years – 65 Years
- Healthy volunteers
- —
Summary
This is a safety and efficacy study of add on therapy with seletracetam in patients experiencing refractory epilepsy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Seletracetam (ucb 44212) |
Timeline
- Start date
- 2006-02-01
- First posted
- 2005-09-15
- Last updated
- 2012-03-20
Source: ClinicalTrials.gov record NCT00175864. Inclusion in this directory is not an endorsement.